☆
Watchlist
Log in
Sign-up
Island Pharmaceuticals Ltd (ila) Logo

Island Pharmaceuticals Ltd (ILA)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

ILA Chart

Snapshot

ILA's Principal Activity is the drug research and repurposing

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -57.31%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 2,204 of 2,413
Sector Rank 192 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies JHL / DVL / CGB
EPS -$0.114
DPS $0.00
Book Value Per Share $0.08

Broker Consensus

ILA is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Island Pharmaceuticals Limited (ILA) is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its lead product candidate is Isla101 for the treatment and/or prevention of mosquito borne viruses, such as dengue fever.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Camberwell VIC 3124
Website www.islandpharmaceuticals.com
Registry Automic Group
Auditor Grant Thornton Audit Pty Ltd
Date Listed 13 Apr 2021

Upcoming Calendar (Forecasted)

Date Event
25/08/2022 Report (Prelim)
25/08/2022 Report (Annual)
13/10/2022 Report (Annual)
23/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr David Lionel Brookes Non-Executive Director Oct 2020

Dr David Lionel Brookes

Non-Executive Director

Dr Brookes has experience in the health and biotechnology industries and has held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI ) in June 2018. He is currently the non-executive Chairman of ASX listed Factor Therapeutics Ltd and of Anatara Lifesciences Ltd . He is currently a non-executive director of ASX listed company TALi Digital Ltd and is the chair of the Audit & Risk committee

Dr David Foster Managing Director Oct 2020

Dr David Foster

Managing Director

Dr Foster has vast experience in the life science industry including 20+ years representing diverse companies, such as pharmaceutical, biotherapeutic and diagnostic companies while in private legal practice. In addition, he served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb. Dr Foster co-founded Roberts Foster LLP- a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies. He is a Board member of bionorthTx and private biotechnology companies. Dr Foster has expertise in formulating intellectual property and business strategies to protect and develop therapeutic assets.

Mr Albert Hansen Non-Executive Director Oct 2020

Mr Albert Hansen

Non-Executive Director

Mr Hansen is currently President of KESA Partners, Inc. (KESA) a family investment office focused on seed investing in life science-related startups. KESA provides capital and strategic management to its portfolio companies. Mr. Hansen serves as President of one of KESA's portfolio companies, Clearlight Biotechnologies, Inc., which has licensed imaging technology for tissue analysis from Stanford University. From 2001 to 2012, Mr. Hansen was a Managing Director of Signet Healthcare Partners, a growth capital private equity firm focused on emerging life science companies. Mr. Hansen has over 25 years of private equity investment experience, with almost 20 years in the life sciences/pharmaceutical field. He is a former Chairman and interim CEO of Questcor Pharmaceuticals, Inc (later acquired for US$5 billion), a former Chairman and interim CEO of Cedarburg Pharmaceuticals Inc. (acquired for US$40 million) and former Chairman of Molecular Medicine Corporation (acquired for US$24 million). KESA Partners, Inc acquired a failing company, Bioserv Corporation, for US$25,000 from NextPharma, Ltd in November 2012. He has also been a director of over ten other private companies. Prior to Signet, Mr Hansen was a principal of Darby Overseas, since acquired by Franklin Templeton. He was also a political appointee as Director of Corporate Finance at the U.S. Treasury Department in 1992. Earlier in his career, Mr Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. He was also an investment banker at E.F. Hutton & Co. Mr Hansen also served in the U.S. Army as an Infantry and Special Forces office

Dr Anna Lavelle Non-Executive Director Oct 2020

Dr Anna Lavelle

Non-Executive Director

Dr Lavelle is an experienced Non-Executive Director serving for over 25 years on the boards of not for profit, government and for profit entities. As Executive Director or Non-Executive Director she has a lengthy track record in healthcare delivery, technology development and negotiating government policy. In 2015 Nature Scientific America, World View ranked Dr Lavelle in the global top 100 "World Visionaries" in biotechnology. Dr Lavelle was the only Australian to be named. From 2005 to 2016, Dr Lavelle was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors. Dr Lavelle is now serving on several boards including - Independent Chair, Medicines Australia Ltd, Independent Chair, Avatar Brokers Pty Ltd, Non- Executive Director Hemideina Pty Ltd, NonExecutive Director Cyban Pty Ltd

Dr Paul MacLeman Executive Chairman,Executive Director May 2020

Dr Paul MacLeman

Executive Chairman,Executive Director

Dr MacLeman has over 25 years' experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Dr MacLeman has expertise in capital raising, business development, technology commercialisation and sales & marketing globally. Dr MacLeman has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Dr MacLeman has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Dr MacLeman is currently Chairman of AdAlta Limited (1AD:ASX), Chairman of SuperTrans Medical Limited and nonexecutive director of Upkara Inc. & Upkara Asia Pacific Pty Ltd. Dr MacLeman Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Dr MacLeman also serves on a number of other NFP and government advisory groups.

Mr Peter Webse Company Secretary N/A

Director Transactions

ILA directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
18/11/21 David Brookes Issued 100,000 $0.25 $25,000 Director remuneration
18/11/21 Albert Hansen Issued 100,000 $0.25 $25,000 Director remuneration
18/11/21 Anna Lavelle Issued 100,000 $0.25 $25,000 Director remuneration

Director Interests

The current holdings of ILA directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Anna Lavelle 18/11/2021 N/A 100,000 400,000 N/A
Albert Hansen 18/11/2021 N/A 10,937,367 423,030 N/A
David Brookes 18/11/2021 N/A 100,000 400,000 N/A
David Foster 30/06/2021 5,146,829 64,564 533,333 N/A
Paul MacLeman 30/06/2021 1 85,053 2,325,000 N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 13, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dr William James Garner 21,090,605 26.05%
Kesa Partners Inc 10,837,367 13.38%
Dr David C Foster 5,146,829 6.36%
Mr Jason Alan Carroll 4,050,000 5.00%
Manchester Explorer Lp 3,774,139 4.66%
Mr Andre Fraga Figueiredo 1,747,947 2.16%
Jeb Partners Lp 1,511,322 1.87%
Mr Phillip Richard Perry 1,210,000 1.49%
BNP Paribas Nominees Pty Ltd- Ib Au Noms Retailclient Drp 971,007 1.20%
Mr Richard M Hemry 679,340 0.84%
Mrs Patricia Fernandes Dias De Almeida 660,861 0.82%
Citicorp Nominees Pty Limited 625,441 0.77%
Mr Alistair Robert Baker 557,537 0.69%
Dr William James Garner I 556,397 0.69%
Mrs Azam Mohsenin-Moshiri 500,000 0.62%
Dr Daniel Tillett 495,918 0.61%
National Nominees Limited 475,000 0.59%
Pac Partners Securities Pty Ltd 440,000 0.54%
Gor Zhirar Karapetyan 407,604 0.50%
Ayers Capital Pty Ltd 405,283 0.50%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 46 293 178 310 80 907

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
KESA PARTNERS INC 13/08/2021 10,837,367 13.38
David Charles Foster 13/08/2021 5,146,829 6.63
William James Garner 19/08/2021 21,913,098 27.06
Jason Alan Carroll 28/04/2022 9,900,000 12.18

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
28-04-22 Jason Alan Carroll 814,391 11.17 12.18
29-03-22 Jason Alan Carroll 835,609 10.15 11.17
01-02-22 Jason Alan Carroll 950,000 9.00 10.15
25-11-21 Jason Alan Carroll 1,625,000 7.00 9.00
19-10-21 Jason Alan Carroll 800,000 6.00 7.00
13-10-21 Jason Alan Carroll 825,000 5.00 6.00
19-08-21 William James Garner 822,493 26.05 27.06
11-08-21 Jason Alan Carroll 4,050,000 -- 5.00

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.268 30 June
ILA Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.